Search Results - "Gavila, J"

Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET) by Jerusalem, G., Mariani, G., Ciruelos, E.M., Martin, M., Tjan-Heijnen, V.C.G., Neven, P., Gavila, J.G., Michelotti, A., Montemurro, F., Generali, D., Simoncini, E., Lang, I., Mardiak, J., Naume, B., Camozzi, M., Lorizzo, K., Bianchetti, S., Conte, P.

“…This European phase IIIb, expanded-access multicenter trial evaluated the safety of EVE plus EXE in a patient population similar to BOLERO-2. Post-menopausal…”
Get full text

Calculation of biomass volume of citrus trees from an adapted dendrometry by Velázquez-Martí, B., Estornell, J., López-Cortés, I., Martí-Gavilá, J.

“…A methodology and computational algorithms, to calculate volumes and the total biomass contained in citrus trees from an adapted dendrometry were developed…”
Get full text

Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study by Gavila, J., Seguí, M. Á., Calvo, L., López, T., Alonso, J. J., Farto, M., Sánchez-de la Rosa, R.

“…Purpose While much progress has been made in the treatment of breast cancer, cardiac complications resulting from therapy remain a significant concern. Both…”
Get full text

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population by Ciruelos, E., Jerusalem, G., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J., Montemurro, F., Generali, D., Lang, I., Martínez-Serrano, M. J., Perelló, M. F., Conte, P.

“…Background The addition of everolimus to exemestane therapy significantly improves progression-free survival in postmenopausal patients with hormone-receptor…”
Get full text

SEOM clinical guidelines in advanced and recurrent breast cancer (2018) by Chacón López-Muñiz, J. I., de la Cruz Merino, L., Gavilá Gregori, J., Martínez Dueñas, E., Oliveira, M., Seguí Palmer, M. A., Álvarez López, I., Antolin Novoa, S., Bellet Ezquerra, M., López-Tarruella Cobo, S.

“…Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to progression and the overall…”
Get full text

Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project by Torregrosa, Mª D., Escudero, M. J., Paredero, I., Carrasco, E., Bermejo, B., Gavila, J., García-Saenz, J., Santaballa, A., Martínez, P., Llombart, A., Andrés, R., Batista, N., Fernández, A., Antón, A., Seguí, M., Gonzalez, S., Ruiz, A.

“…Introduction An increase in the number of cancer cases is expected in the near future. Breast cancer (BC) mortality rates increase with age even when adjusted…”
Get full text

Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors by Andreu, Y., Soto-Rubio, A., Ramos-Campos, M., Escriche-Saura, A., Martínez, M., Gavilá, J.

“…To explore the modulatory role of Adjuvant Hormone Therapy (AHT) on health-related quality of life (QoL), subjective well-being and distress prevalence in…”
Get full text

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy by Jerusalem, G., Farah, S., Courtois, A., Chirgwin, J., Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M.P., Simoncini, E., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O’Reilly, S., Gombos, A., Ruhstaller, T., Burstein, H.J., Rabaglio, M., Ruepp, B., Ribi, K., Viale, G., Gelber, R.D., Coates, A.S., Loi, S., Goldhirsch, A., Regan, M.M., Colleoni, M.

“…Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of…”
Get full text

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane by Guerrero, A., Gavilá, J., Folkerd, E., Ortiz, B., Martínez, F., García, A., Climent, M.A., Guillem, V., Ruíz, A.

“…Aromatase inhibitors (AIs) may promote ovarian function recovery (OFR). True incidence, predictors and impact on the outcome of OFR are unknown. We carried out…”
Get full text

Estimation of structural attributes of walnut trees based on terrestrial laser scanning by J. Estornell, A. Velázquez-Martí, A. Fernández-Sarría, I. López-Cortés, J. Martí-Gavilá, D. Salazar

“…Juglans regia L. (walnut) is a tree of significant economic importance, usually cultivated for its seed used in the food market, and for its wood used in the…”
Get full text

SEOM clinical guidelines on cardiovascular toxicity (2018) by Virizuela, J. A., García, A. M., de las Peñas, R., Santaballa, A., Andrés, R., Beato, C., de la Cruz, S., Gavilá, J., González-Santiago, S., Fernández, T. L.

“…One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor’s prognosis. Cardiotoxicity…”
Get full text

Gestational breast cancer: distinctive molecular and clinico-epidemiological features by de la Haba-Rodríguez, J. R., Mínguez, P., Rojo, F., Martín, M., Alba, E., Servitja, S., Prat, A., Pérez-Fidalgo, J. A., Gavilá, J., Morales, C., Rodriguez-Lescure, A., Herrero, C., Peña-Enriquez, R, Herranz, J., Hernando, C., Hernández-Blanquisett, A., Guil-Luna, S., Martinez, MT, Blanch, S., Caballero, R., Martín, N., Pollán, M., Guerrero-Zotano, A., Bermejo, B.

“…Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6–15% of BC cases in…”
Get full text

SEOM clinical guidelines in metastatic breast cancer 2015 by Gavilá, J., Lopez-Tarruella, S., Saura, C., Muñoz, M., Oliveira, M., De la Cruz-Merino, L., Morales, S., Alvarez, I., Virizuela, J. A., Martin, M.

“…Metastatic breast cancer is essentially an incurable disease. However, recent advances have resulted in a significant improvement of overall survival. The SEOM…”
Get full text

Preclinical and clinical development of palbociclib and future perspectives by de Dueñas, E. Martínez, Gavila-Gregori, J., Olmos-Antón, S., Santaballa-Bertrán, A., Lluch-Hernández, A., Espinal-Domínguez, E. J., Rivero-Silva, M., Llombart-Cussac, A.

“…Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and…”
Get full text

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study by Gavilá, J., De La Haba, J., Bermejo, B., Rodríguez-Lescure, Á., Antón, A., Ciruelos, E., Brunet, J., Muñoz-Couselo, E., Santisteban, M., Rodríguez Sánchez, C. A., Santaballa, A., Sánchez Rovira, P., García Sáenz, J. Á., Ruiz-Borrego, M., Guerrero-Zotano, A. L., Huerta, M., Cotes-Sanchís, A., Lao Romera, J., Aguirre, E., Cortés, J., Llombart-Cussac, A.

“…Purpose To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients…”
Get full text

Replied to “Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)” by Virizuela, J. A., Garcia, A. Martin, de las Peñas, R., Santaballa, A., Andrés, R., Beato, C., de la Cruz, S., Gavilá, J., González-Santiago, S., Fernández, T. López

Get full text

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain by Ciruelos, E., Vidal, M., Martínez de Dueñas, E., Martínez-Jáñez, N., Fernández, Y., García-Sáenz, J. A., Murillo, L., Carabantes, F., Beliera, A., Fonseca, R., Gavilá, J.

“…Background Everolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced…”
Get full text

35 High pathologic complete remission rate with liposome-encapsulated doxorubicin + paclitaxel + trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience by Gavila, J, Guerrero-Zotano, A, Climent, M.A, Blanch, S, Guillem, V, Camp, J, Tortajada, M.I, Gozalbo, F, Vidal, P, Ruiz, A

Get full text

Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment? by Cejalvo, Juan Miguel, Falato, Claudette, Villanueva, Lorea, Tolosa, Pablo, González, Xavier, Pascal, Mariona, Canes, Jordi, Gavilá, Joaquín, Manso, Luis, Pascual, Tomás, Prat, Aleix, Salvador, Fernando

“…•The goal of immunotherapy in cancer is to overcome immunosuppression induced by the tumour and its microenvironment, thereby allowing the immune system to…”
Get full text

Trajectories of alcohol consumption during life and the risk of developing breast cancer by Donat-Vargas, Carolina, Guerrero-Zotano, Ángel, Casas, Ana, Baena-Cañada, José Manuel, Lope, Virginia, Antolín, Silvia, Garcia-Saénz, José Ángel, Bermejo, Begoña, Muñoz, Montserrat, Ramos, Manuel, de Juan, Ana, Jara Sánchez, Carlos, Sánchez-Rovira, Pedro, Antón, Antonio, Brunet, Joan, Gavilá, Joaquín, Salvador, Javier, Arriola Arellano, Esperanza, Bezares, Susana, Fernández de Larrea-Baz, Nerea, Pérez-Gómez, Beatriz, Martín, Miguel, Pollán, Marina

“…Background Whether there are lifetime points of greater sensitivity to the deleterious effects of alcohol intake on the breasts remains inconclusive. Objective…”
Get full text